Use of bremelanotide in patients with controlled hypertension

A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction, said method comprising administering more than a single subcutaneous injection of a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide to the female patient when the patient is anticipating sexual activity, the composition comprising 1.25 mg to 1.75 mg net peptide weight of bremelanotide sufficient to result in a peak plasma concentration of bremelanotide of no more than 120 ng/mL within 60 minutes after administration of the composition, wherein the female patient also has controlled hypertension, and wherein there is at least 24 hours between each injection and no more than eight injections are administered in a month, thereby treating female sexual dysfunction.

A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction, said method comprising administering more than a single subcutaneous injection of a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide to the female patient when the patient is anticipating sexual activity, the composition comprising an amount of bremelanotide sufficient to result in a peak plasma concentration of bremelanotide of no more than 120 ng/ml within 60 minutes after administration of the composition, wherein the composition comprises 1.50 mg to 1.75 mg net peptide weight of bremelanotide, wherein the female patient also has controlled hypertension, and wherein there is at least 24 hours between each injection and no more than eight injections are administered in a month, thereby treating female sexual dysfunction.